TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
26 hedge funds and large institutions have $18.7M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
49% more capital invested
Capital invested by funds: $12.6M → $18.7M (+$6.12M)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
0% more funds holding
Funds holding: 26 → 26 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.59M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$372K |
| 3 |
Renaissance Technologies
New York
|
+$110K |
| 4 |
BlackRock
New York
|
+$104K |
| 5 |
VF
Virtu Financial
New York
|
+$61.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.09M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$124K |
| 3 |
QF
QVT Financial
New York
|
-$81.8K |
| 4 |
SI
SII Investments
Appleton,
Wisconsin
|
-$61K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWM
26
Perigon Wealth Management
San Francisco,
California
| $1K | +$1.04K | +2 | New |
|
|
27
Franklin Resources
San Mateo,
California
| – | -$1.09M | -2,266 | Closed |
|
|
28
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$124K | -258 | Closed |
|
|
SI
29
SII Investments
Appleton,
Wisconsin
| – | -$61K | -128 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$5K | -11 | Closed |
|
31
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -4 | Closed |
|
|
AIM
32
Acrospire Investment Management
Chicago,
Illinois
| – | -$1K | -2 | Closed |
|
TCON Hedge Fund Activity: Q3 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2017, worth a combined $18.7M — up 49% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TCON positions and 6 closed out — a net gain of 2 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $2.59M. The largest seller was Franklin Resources, exiting entirely with an estimated $1.09M sold.
- 26 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $18.7M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2017, up 49% quarter-over-quarter.
- 8 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 6 closed out, a net change of +2 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was 683 Capital Management, an estimated $2.59M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Franklin Resources, an estimated $1.09M sold.
Based on aggregated 13F filings for Q3 2017.